Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
Bristol Myers Squibb is leading Pathos AI's Series E financing and securing three-year exclusive rights to Pathos Foundry in neuroscience, plus broader non-exclusive access across its R&D portfolio. The collaboration pairs Pathos's agentic AI with a Tempus-built de-identified dataset covering hundreds of thousands of neurological-disease patients, which Pathos licenses under a five-year, $55 million agreement.
Key figures
- Deal Value Usd
- 55000000
- License amount
- $55 million
- Financing round
- Series E
- License term years
- 5
- Exclusivity term years
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.